The value of tumour weight as a predictive factor for recurrence and progression in non-muscle invasive bladder cancer

Fernández-Conejo, Guillermo; Peña, Enrique de la; Hernández, Virginia; Guijarro, A.; Castro, Alejandro; Pérez‐Fernández, Elia; Llorente, C.

doi:10.1080/21681805.2019.1708968

Cited by 5 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After screening, a full‐text review was performed for 201 articles. According to the inclusion criteria, we finally identified 72 studies comprising 28 139 patients eligible for the meta‐analysis [12–83]. The demographics of each included study are shown in Table 1 and Table S2.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Oncological impact of cystoscopic findings in non‐muscle‐invasive bladder cancer: a meta‐analysis

et al. 2023

View full text Add to dashboard Cite

Objective To assess the association between cystoscopic findings and oncological outcomes in patients with non‐muscle‐invasive bladder cancer (NMIBC) given that the oncological impact of quantity and quality assessment of tumours with cystoscopy has not been well verified. Methods Multiple databases were queried in May 2022 for studies investigating the association of oncological outcomes, such as recurrence‐free (RFS), progression‐free (PFS), and cancer‐specific survival (CSS), with cystoscopic findings, including multiplicity, size, and gross appearance of tumours in patients with NMIBC. Results Overall, 73 studies comprising 28 139 patients were eligible for the meta‐analysis. Tumour multiplicity was associated with worse RFS (pooled hazard ratio [HR] 1.61, 95% confidence interval [CI] 1.48–1.74) and PFS (pooled HR 1.44, 95% CI 1.18–1.76) in NMIBC patients (including both Ta and T1). Tumour size (≥3 cm) was associated with worse RFS (pooled HR 1.97, 95% CI 1.69–2.30) and PFS (pooled HR 1.81, 95% CI 1.52–2.15) in NMIBC patients. In patients with T1 bladder cancer (BCa), tumour multiplicity and size (≥3 cm) were also associated with worse RFS, PFS and CSS. By contrast, among patients treated with bacillus Calmette‐Guérin (BCG), tumour multiplicity was not associated with worse RFS, and tumour size (≥3 cm) was not associated with worse PFS. Sessile tumours were associated with worse RFS (pooled HR 2.14, 95% CI 1.52–3.01) and PFS (pooled HR 2.17, 95% CI 1.42–3.32) compared to pedunculated tumours. Compared to papillary tumours, solid tumours were associated with worse RFS (pooled HR 1.84, 95% CI 1.25–2.72) and PFS (pooled HR 3.06, 95% CI 2.31–4.07) in NMIBC patients, and CSS in T1 BCa patients (pooled HR 2.32, 95% CI 1.63–3.30). Conclusions Cystoscopic findings, including tumour multiplicity, size, and gross appearance, strongly predict oncological outcomes in NMIBC patients. Cystoscopic visual features can help in the decision‐making process regarding the timeliness and extent of tumour resection as well as future management such as intravesical therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Of the 72 included studies, five included only Ta NMIBC patients [12–16], and 26 studies included only T1 NMIBC patients [17–42]. The other 41 studies included both Ta and T1 patients [43–83].…”

Section: Resultsmentioning

confidence: 99%

Oncological impact of cystoscopic findings in non‐muscle‐invasive bladder cancer: a meta‐analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…22,23 They have improved the outcomes of BC treatment remarkably but not fundamentally, mainly due to little knowledge about its pathogenesis, making early diagnosis and treatment difficult. 24,25 Therefore, it is necessary to find new molecular targets for the early diagnosis and treatment of BC. LRRC59 is a transmembrane protein that is mainly distributed in the ER and nuclear membrane, with its C-terminal short region facing the ER lumen and four LRRs and coiling domains facing the cytoplasm.…”

Section: Discussionmentioning

confidence: 99%

“…Based on the classical treatment modalities such as transurethral tumor resection, intravesical chemotherapy, and radical cystectomy, drugs such as ICIs (PD‐1/PD‐L1 monoclonal antibodies) have been developed in recent years 22,23 . They have improved the outcomes of BC treatment remarkably but not fundamentally, mainly due to little knowledge about its pathogenesis, making early diagnosis and treatment difficult 24,25 . Therefore, it is necessary to find new molecular targets for the early diagnosis and treatment of BC.…”

Section: Discussionmentioning

confidence: 99%

LRRC59 serves as a novel biomarker for predicting the progression and prognosis of bladder cancer

Zhang,

Xie,

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

BackgroundLeucine‐rich repeat‐containing protein 59 (LRRC59) is an endoplasmic reticulum membrane protein involved in various cancers, but its role in bladder cancer (BC) has not been reported. The aim of the present study was to investigate the role of LRRC59 protein in BC progression and prognosis.MethodsThe expression profile and clinical significance were retrieved from BC patients in the Cancer Genome Atlas database. The methylation status of LRRC59 was analyzed by UALCAN and MethSurv databases. Potential signaling pathways and biological functions were explored by functional enrichment analysis. Immunocyte infiltration was evaluated by CIBERSORT analysis. The prognostic value of LRRC59 was evaluated by Kaplan–Meier and Cox regression analyses. Overall survival (OS) was predicted by the nomogram plot established in this study. LRRC59 expression in 10 pairs BC and adjacent noncancerous tissues were analyzed by immunohistochemistry (IHC). Cell proliferation, migration, and invasion were detected by CCK8, colony formation assay, transwell assay, and cell scratch assay, respectively. Proteins related to epithelial–mesenchymal transition and apoptosis were detected by western blot.ResultsLRRC59 overexpression significantly decreased OS, disease‐specific survival, and progress‐free interval of BC patients. LRRC59 was a prognostic marker for OS and its hypomethylation status signified a poor prognosis. LRRC59 overexpression was correlated with infiltration of resting memory CD4 T cells, memory activated CD4 T cells, resting NK cells, macrophages M0, M1, M2, and neutrophils. IHC showed that the LRRC59 expression in BC tissue was significantly higher than that in adjacent noncancerous tissue. Knockdown of LRRC59 expression inhibited the proliferation of BC cells and reduced their migratory ability. Western blot showed that Snail and vimentin protein expressions decreased, while E‐cadherin expressions increased.ConclusionsLRRC59 expression can predict the outcome of BC independently and serve as a new biomarker for diagnosis.

show abstract

“…Most patients with bladder cancer (i.e., 70%) are initially diagnosed as NMIBC. The standard treatment for NMIBC typically involves transurethral resection of bladder tumors (TURBT); however, around 30% of patients still experience postoperative recurrence. − The landscape of bladder cancer treatment has been evolving with the advent of immunotherapy. − For example, immune checkpoint inhibitors (ICIs), which target specific inhibitory checkpoint molecules expressed on antigen-presenting cells and T cells, have emerged as powerful weapons against cancer. Despite the great potential, ICIs not only promote antitumor immune activity but also carry the risk of boosting T-cell reactivity against healthy tissues and organs, − leading to adverse reactions similar to those of autoimmune syndromes.…”

Section: Introductionmentioning

confidence: 99%

Endoplasmic Reticulum-Targeting AIE Photosensitizers to Boost Immunogenic Cell Death for Immunotherapy of Bladder Carcinoma

Miao,

Li,

Zeng

et al. 2023

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Bladder cancer is characterized by high rates of recurrence and multifocality. Immunogenic cell death (ICD) of cancer cells has emerged as a promising strategy to improve the immunogenicity of tumor cells for enhanced cancer immunotherapy. Although photosensitizer-based photodynamic therapy (PDT) has been validated as capable of inducing ICD in cancer cells, the photosensitizers with a sufficient ICD induction ability are still rare, and there have been few reports on the development of advanced photosensitizers to strongly evoke the ICD of bladder cancer cells for eliciting potent antitumor immune responses and eradicating bladder carcinoma in situ. In this work, we have synthesized a new kind of endoplasmic reticulum (ER)-targeting aggregation-induced emission (AIE) photosensitizer (named DPASCP-Tos), which could effectively anchor to the cellular ER and trigger focused reactive oxygen species (ROS) production within the ER, thereby boosting ICD in bladder cancer cells. Furthermore, we have demonstrated that bladder cancer cells killed by ER-targeted PDT could serve as a therapeutic cancer vaccine to elicit a strong antitumor immunity. Prophylactic vaccination of the bladder cancer cells killed by DPASCP-Tos under light irradiation promoted the maturation of dendritic cells (DCs) and the expansion of tumor antigen-specific CD8 + T cells in vivo and protected mice from subsequent in situ bladder tumor rechallenge and extended animal survival. In summary, the ER-targeted AIEgens developed here significantly amplified the ICD of bladder cells through focused ROS-based ER oxidative stress and transformed bladder cancer cells into the therapeutic vaccine to enhance immunogenicity against orthotopic bladder cancer, providing valuable insights for bladder carcinoma treatment.

show abstract

The value of tumour weight as a predictive factor for recurrence and progression in non-muscle invasive bladder cancer

Cited by 5 publications

References 12 publications

Oncological impact of cystoscopic findings in non‐muscle‐invasive bladder cancer: a meta‐analysis

Oncological impact of cystoscopic findings in non‐muscle‐invasive bladder cancer: a meta‐analysis

LRRC59 serves as a novel biomarker for predicting the progression and prognosis of bladder cancer

Endoplasmic Reticulum-Targeting AIE Photosensitizers to Boost Immunogenic Cell Death for Immunotherapy of Bladder Carcinoma

Contact Info

Product

Resources

About